All News

Lupusfoto.jpg

Belimumab in SLE with Mucocutaneous or Vasculitis Findings

d Jack Cush, MD

A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.

Read Article
heart

Valves Gone Wild in SLE

d Melissa Akselrad, MD

Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis, which is characterized by the presence of sterile vegetations on the heart valves.

Read Article
Dafna Gladman

50 Year Perspective on Lupus

d Dafna Gladman, MD

An observational cohort study was started in Toronto by Dr. Murray Urowitz in 1970. The program was set up as a specialized clinic to provide care for patients with lupus, to study clinical laboratory correlations in the disease, and to better understand long-term outcomes of the disease. What have we learned from more than 50 years of follow-up of patients with lupus? Some of the important observations include the following.

Read Article
CPPDwrist.JPG

Genetic Link to CPPD

d EurekAlert!

In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) disease in Americans of European and African descent.

Read Article
Checklist survey

Contemporary lupus nephritis treatment

d Janet Pope, MD, MPH, FRCPC

Outcomes in lupus nephritis are akin to the glass half full. Serial monotherapy is out, as the percentage who achieved a complete renal response was very low and some went to end stage kidney disease (ESKD). Solutions?

Read Article
SLE.organ_.jpg

2025 ACR Guideline for the Treatment of SLE

d Jack Cush, MD

The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. 

Read Article
IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/sbXW6vNX5y
Dr. John Cush RheumNow ( View Tweet)
Moving Targets in Lupus and Lupus Trials In the 1990s, developing lupus treatments became a priority, but success was elusive for 20 years. Belimumab was approved by showing only small differences from placebo in trials with 867 patients globally. Its efficacy was confirmed by https://t.co/TekxzTJjwC
Dr. John Cush RheumNow ( View Tweet)
Steroids in Lupus Nephritis: No Free Lunch https://t.co/yPQuZcnRLH https://t.co/V8GZoslSqV

Links:

Dr. John Cush RheumNow ( View Tweet)
NEW for #LUPUS2025—@ern_reconnet–SLICC–@SLEuroSociety expert consensus on the therapeutic management of rare systemic #lupus erythematosus manifestations https://t.co/XwAHpsho57 Free to read with registration on https://t.co/28wkm5ab69 (also free) @Lupusreference #SLE https://t.co/73K0DKTHye

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)
🔺CTD-ILD radiological signs to look out for 👀 #CTD #ILD #UIP #NSIP #Fibrosis #scleroderma #systemicsclerosis #Sjogrens #Lupus By @IlliasulK https://t.co/hHupTz0bCy

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
JAK inhibitors reduce inflammation while potentially exacerbating the propagation viral infections. They suppress transcription of IFN-stimulated genes in non-infected cells (usually triggered by type I IFNs produced by infected cells) Thus facilitating viral propagation https://t.co/BDzz8pHKxL
Dr. John Cush RheumNow ( View Tweet)
MMWR: 1994 the U.S. Vaccines for Children program has covered the cost of vaccines for US children. Since 1994 routine child vaccinations will have prevented ~508 million illness, 32 million hospitalizations, & 1,129,000 deaths,; direct savings of $540 billion & societal savings https://t.co/JCeSFmIgxV
Dr. John Cush RheumNow ( View Tweet)
Biologics in Pregnancy Patients With Autoimmune Disease A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients https://t.co/fjtUNaYtp9
Dr. John Cush RheumNow ( View Tweet)
Shifting the Management Paradigm for SLE and Lupus Nephritis The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes. https://t.co/idxMBTyTwp https://t.co/unxmjVst3D

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/AkuvCl6nG6
Dr. John Cush RheumNow ( View Tweet)
5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0. 61), & gout (HR 0. 63) vs sitagliptin. Semaglutided did not lower the risk of Knee (HR 1. 05) or hip osteoarthritis (HR 0. 88). https://t.co/MqMBKdsXlu https://t.co/OlB2liBZ69

Links:

Dr. John Cush RheumNow ( View Tweet)
Diagnosing Neuropsychiatric SLE (5.23.2025) Dr. Jack Cush reviews the news and journal reports from RheumNow - including views on the vagus nerve, NPSLE and CAR-T mania. https://t.co/PadauvfWWA https://t.co/4k4nfHSPg5

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab https://t.co/fBdfrrZt1M
Dr. John Cush RheumNow ( View Tweet)
Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% osteoarthritis, and 11.2% regional pain syndromes. Another German study showed low risk of IRD if CRP <5 https://t.co/v5qYb7c7jP https://t.co/iq4NfcC3cH https://t.co/6lkTMSBUqc

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×